No Cover Image

Journal article 72 views 4 downloads

Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses

Richard P. C. Coomer Orcid Logo, Janine A. Terschuur Orcid Logo, M. Chiara Pressanto Orcid Logo, Ian Walker Orcid Logo

Veterinary Surgery, Volume: 53, Issue: 1, Pages: 175 - 183

Swansea University Author: Ian Walker Orcid Logo

  • 68982.VoR.pdf

    PDF | Version of Record

    © 2023 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License.

    Download (933.59KB)

Check full text

DOI (Published version): 10.1111/vsu.14030

Abstract

ObjectiveTo assess the efficacy of commercial intra-articular blood-derived allogeneic-induced mesenchymal stem cells (CIMSCs) to treat tarsometatarsal lameness in horses.Study designThis was a retrospective cohort study.AnimalsRecords from 167 adult light breed horses with bilateral tarsometatarsal...

Full description

Published in: Veterinary Surgery
ISSN: 0161-3499 1532-950X
Published: Wiley 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa68982
first_indexed 2025-02-27T14:25:17Z
last_indexed 2025-03-12T05:35:42Z
id cronfa68982
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2025-03-11T14:42:39.4270139</datestamp><bib-version>v2</bib-version><id>68982</id><entry>2025-02-27</entry><title>Allogeneic chondrogenic&#x2010;induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses</title><swanseaauthors><author><sid>ac9a28ab033f55f1a469ab76e12feb96</sid><ORCID>0000-0002-0079-3149</ORCID><firstname>Ian</firstname><surname>Walker</surname><name>Ian Walker</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-02-27</date><abstract>ObjectiveTo assess the efficacy of commercial intra-articular blood-derived allogeneic-induced mesenchymal stem cells (CIMSCs) to treat tarsometatarsal lameness in horses.Study designThis was a retrospective cohort study.AnimalsRecords from 167 adult light breed horses with bilateral tarsometatarsal lameness.MethodsHorses with tarsometatarsal lameness were retrospectively selected from medical records. Diagnosis followed subjective graded lameness assessment before and after intra-articular analgesia, with graded radiographic tarsal examination. Horses were excluded if they were diagnosed or treated for any other concurrent lameness conditions during the study. Time to last follow-up and time of recurrence of lameness was recorded at veterinary re-assessment.ResultsA total of 67 horses were recruited to the CIMSC-treated group and 100 to the corticosteroid (CS)-treated group. Median age was 9&#x2009;years, with no difference in signalment, use or radiographic grade between groups. First re-examination was 38&#x2009;days (95% CI: 38&#x2013;49), with no difference between groups, CIMSC 42 (35&#x2013;45), control 34 (25&#x2013;42). Median follow-up was 438&#x2009;days for CIMSC, 546 for controls. Symptoms of lameness recurred in 86/100 controls compared to 17/67 (25%) CIMSC. Median time to lameness recurring in CIMSC was 336&#x2009;days (95% CI: 239&#x2013;400), control 90&#x2009;days (95% CI: 80&#x2013;108), p&#x2009;&lt;&#x2009;.0001. Cox proportional hazard ratio for treatment was 8.35, 95% CI: 4.67 to 14.92, p&#x2009;&lt;&#x2009;.0001.ConclusionsLameness was abolished in all treated horses. It recurred significantly less often, and later, in CIMSC-treated horses.Clinical significanceIntra-articular CIMSC treatment results in prolonged soundness in horses with tarsometatarsal lameness.</abstract><type>Journal Article</type><journal>Veterinary Surgery</journal><volume>53</volume><journalNumber>1</journalNumber><paginationStart>175</paginationStart><paginationEnd>183</paginationEnd><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0161-3499</issnPrint><issnElectronic>1532-950X</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-01-01</publishedDate><doi>10.1111/vsu.14030</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><apcterm>Other</apcterm><funders/><projectreference/><lastEdited>2025-03-11T14:42:39.4270139</lastEdited><Created>2025-02-27T14:18:16.6565932</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">School of Psychology</level></path><authors><author><firstname>Richard P. C.</firstname><surname>Coomer</surname><orcid>0000-0002-8023-3079</orcid><order>1</order></author><author><firstname>Janine A.</firstname><surname>Terschuur</surname><orcid>0000-0001-5749-6703</orcid><order>2</order></author><author><firstname>M. Chiara</firstname><surname>Pressanto</surname><orcid>0000-0002-0998-5059</orcid><order>3</order></author><author><firstname>Ian</firstname><surname>Walker</surname><orcid>0000-0002-0079-3149</orcid><order>4</order></author></authors><documents><document><filename>68982__33782__0d311fb06db54397885fa426809114fc.pdf</filename><originalFilename>68982.VoR.pdf</originalFilename><uploaded>2025-03-11T14:40:45.5145026</uploaded><type>Output</type><contentLength>956000</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2023 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2025-03-11T14:42:39.4270139 v2 68982 2025-02-27 Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses ac9a28ab033f55f1a469ab76e12feb96 0000-0002-0079-3149 Ian Walker Ian Walker true false 2025-02-27 ObjectiveTo assess the efficacy of commercial intra-articular blood-derived allogeneic-induced mesenchymal stem cells (CIMSCs) to treat tarsometatarsal lameness in horses.Study designThis was a retrospective cohort study.AnimalsRecords from 167 adult light breed horses with bilateral tarsometatarsal lameness.MethodsHorses with tarsometatarsal lameness were retrospectively selected from medical records. Diagnosis followed subjective graded lameness assessment before and after intra-articular analgesia, with graded radiographic tarsal examination. Horses were excluded if they were diagnosed or treated for any other concurrent lameness conditions during the study. Time to last follow-up and time of recurrence of lameness was recorded at veterinary re-assessment.ResultsA total of 67 horses were recruited to the CIMSC-treated group and 100 to the corticosteroid (CS)-treated group. Median age was 9 years, with no difference in signalment, use or radiographic grade between groups. First re-examination was 38 days (95% CI: 38–49), with no difference between groups, CIMSC 42 (35–45), control 34 (25–42). Median follow-up was 438 days for CIMSC, 546 for controls. Symptoms of lameness recurred in 86/100 controls compared to 17/67 (25%) CIMSC. Median time to lameness recurring in CIMSC was 336 days (95% CI: 239–400), control 90 days (95% CI: 80–108), p < .0001. Cox proportional hazard ratio for treatment was 8.35, 95% CI: 4.67 to 14.92, p < .0001.ConclusionsLameness was abolished in all treated horses. It recurred significantly less often, and later, in CIMSC-treated horses.Clinical significanceIntra-articular CIMSC treatment results in prolonged soundness in horses with tarsometatarsal lameness. Journal Article Veterinary Surgery 53 1 175 183 Wiley 0161-3499 1532-950X 1 1 2024 2024-01-01 10.1111/vsu.14030 COLLEGE NANME COLLEGE CODE Swansea University Other 2025-03-11T14:42:39.4270139 2025-02-27T14:18:16.6565932 Faculty of Medicine, Health and Life Sciences School of Psychology Richard P. C. Coomer 0000-0002-8023-3079 1 Janine A. Terschuur 0000-0001-5749-6703 2 M. Chiara Pressanto 0000-0002-0998-5059 3 Ian Walker 0000-0002-0079-3149 4 68982__33782__0d311fb06db54397885fa426809114fc.pdf 68982.VoR.pdf 2025-03-11T14:40:45.5145026 Output 956000 application/pdf Version of Record true © 2023 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License. true eng http://creativecommons.org/licenses/by-nc-nd/4.0/
title Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses
spellingShingle Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses
Ian Walker
title_short Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses
title_full Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses
title_fullStr Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses
title_full_unstemmed Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses
title_sort Allogeneic chondrogenic‐induced mesenchymal stem cells for the treatment of tarsometatarsal lameness in horses
author_id_str_mv ac9a28ab033f55f1a469ab76e12feb96
author_id_fullname_str_mv ac9a28ab033f55f1a469ab76e12feb96_***_Ian Walker
author Ian Walker
author2 Richard P. C. Coomer
Janine A. Terschuur
M. Chiara Pressanto
Ian Walker
format Journal article
container_title Veterinary Surgery
container_volume 53
container_issue 1
container_start_page 175
publishDate 2024
institution Swansea University
issn 0161-3499
1532-950X
doi_str_mv 10.1111/vsu.14030
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str School of Psychology{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}School of Psychology
document_store_str 1
active_str 0
description ObjectiveTo assess the efficacy of commercial intra-articular blood-derived allogeneic-induced mesenchymal stem cells (CIMSCs) to treat tarsometatarsal lameness in horses.Study designThis was a retrospective cohort study.AnimalsRecords from 167 adult light breed horses with bilateral tarsometatarsal lameness.MethodsHorses with tarsometatarsal lameness were retrospectively selected from medical records. Diagnosis followed subjective graded lameness assessment before and after intra-articular analgesia, with graded radiographic tarsal examination. Horses were excluded if they were diagnosed or treated for any other concurrent lameness conditions during the study. Time to last follow-up and time of recurrence of lameness was recorded at veterinary re-assessment.ResultsA total of 67 horses were recruited to the CIMSC-treated group and 100 to the corticosteroid (CS)-treated group. Median age was 9 years, with no difference in signalment, use or radiographic grade between groups. First re-examination was 38 days (95% CI: 38–49), with no difference between groups, CIMSC 42 (35–45), control 34 (25–42). Median follow-up was 438 days for CIMSC, 546 for controls. Symptoms of lameness recurred in 86/100 controls compared to 17/67 (25%) CIMSC. Median time to lameness recurring in CIMSC was 336 days (95% CI: 239–400), control 90 days (95% CI: 80–108), p < .0001. Cox proportional hazard ratio for treatment was 8.35, 95% CI: 4.67 to 14.92, p < .0001.ConclusionsLameness was abolished in all treated horses. It recurred significantly less often, and later, in CIMSC-treated horses.Clinical significanceIntra-articular CIMSC treatment results in prolonged soundness in horses with tarsometatarsal lameness.
published_date 2024-01-01T12:43:19Z
_version_ 1827207642124124160
score 10.905303

Similar Items